Evidence map›Paper›PMID 34643220›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Resistance in Enterobacterales Is Higher Among People Living With Human Immunodeficiency Virus.

Heather I Henderson, Sonia Napravnik, Emily W Gower, Allison E Aiello, Alan C Kinlaw, Billy Williams, David A Wohl, David van Duin

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Multidrug-Resistant Bacteria in Immunocompromised Patients.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Heather I HendersonDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-2197-3149
Sonia NapravnikDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Emily W GowerDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Allison E AielloDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Alan C KinlawDivision of Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill School of Pharmacy, Chapel Hill, North Carolina, USA.
Billy WilliamsClinical Microbiology Laboratory, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA.
David A WohlDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
David van DuinDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0003-4784-3227

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Training in Infectious Disease Epidemiology (TIDE)T32AI070114 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Brian W Pence · 2007 to 2026
$4.0M
North Carolina Translational and Clinical Science Institute (NC TraCS) TL1TL1TR002491 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROY-CHAUDHURY, PRABIR · 2018 to 2022
$1.5M
NCATS NIH HHS TL1 TR002491NIAID NIH HHS P30 AI050410NIAID NIH HHS T32 AI070114
6 · The paper itself

Abstract

backgroundMultidrug-resistant Enterobacterales (MDR-E) are important pathogens. People living with human immunodeficiency virus (HIV; PLWH) may be at greater risk for MDR-E infection given relatively high antibiotic exposure and burden of comorbidities.

methodsWe analyzed data from 36 521 patients in a healthcare system in North Carolina who had a clinical culture with growth of an Enterobacterales species from 2000 to 2018; 440 were PLWH. We used generalized linear models to estimate prevalence ratios and differences, contrasting PLWH and people not living with HIV (PNLWH) for resistance to individual antibiotic classes, as well as MDR-E. We assessed trends in prevalence over time by calculating the 5-year moving average and fitting restricted cubic spline models.

resultsThe overall prevalence of MDR-E was higher among PLWH (21.5%; 95% confidence interval [CI], 18.2%-25.1%) vs PNLWH (16.5%; 95% CI, 16.2%-16.9%), with an adjusted prevalence ratio of 1.38 (95% CI, 1.14-1.65). PLWH had higher rates of antimicrobial resistance than PNLWH for all antibiotic classes analyzed, including penicillins, penicillin/beta lactamase inhibitor combinations, and sulfonamides. MDR-E prevalence was 3 to 10 percentage points higher among PLWH than PNLWH throughout the study period based on the 5-year moving average.

conclusionsIn a large clinical study population in the southeastern United States from 2000 to 2018, the prevalence of antibacterial resistance among Enterobacterales was consistently higher among PLWH than PNLWH. These data highlight the importance of identifying and mitigating the factors that contribute to antimicrobial resistance in PLWH, given the potential clinical consequences of these resistant pathogens.

Indexed as

HIV InfectionsAnti-Bacterial AgentsComorbidityHIVHumansNorth CarolinaAnti-Bacterial Agentsantimicrobial-resistant EnterobacteralesepidemiologyHIV

Identifiers

PMID34643220
PMCPMC9402620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.